Organovo Holdings (NASDAQ: ONVO) is one of 197 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its rivals? We will compare Organovo Holdings to similar businesses based on the strength of its analyst recommendations, earnings, valuation, dividends, profitability, institutional ownership and risk.
This table compares Organovo Holdings and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Organovo Holdings Competitors||-3,961.56%||-120.07%||-44.67%|
This is a summary of recent recommendations and price targets for Organovo Holdings and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Organovo Holdings Competitors||469||2236||6133||118||2.66|
Organovo Holdings presently has a consensus target price of $6.94, indicating a potential upside of 362.50%. As a group, “Biotechnology & Medical Research” companies have a potential downside of 0.01%. Given Organovo Holdings’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Organovo Holdings is more favorable than its rivals.
Institutional & Insider Ownership
23.9% of Organovo Holdings shares are owned by institutional investors. Comparatively, 46.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 10.2% of Organovo Holdings shares are owned by company insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Risk & Volatility
Organovo Holdings has a beta of 3.02, meaning that its share price is 202% more volatile than the S&P 500. Comparatively, Organovo Holdings’ rivals have a beta of 1.63, meaning that their average share price is 63% more volatile than the S&P 500.
Valuation & Earnings
This table compares Organovo Holdings and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Organovo Holdings||$4.33 million||-$38.77 million||-3.85|
|Organovo Holdings Competitors||$207.83 million||-$2.34 million||0.17|
Organovo Holdings’ rivals have higher revenue and earnings than Organovo Holdings. Organovo Holdings is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
About Organovo Holdings
Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.
What are top analysts saying about Organovo Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Organovo Holdings Inc. and related companies.